Abeona Therapeutics Q1 net loss $9.1M; cash runway into Q3 2024; advancing EB-101 BLA submission

ABEONA THERAPEUTICS INC.

2024-Q1 EPS reported -$0.54

Net loss of $9.1M ($0.54 loss per share) vs $22.0M ($3.80) in Q1 2022; license revenue nil.
Cash, equivalents, short-term investments $40.7M at Mar 31, 2023, down from $52.5M at Dec 31, 2022; cash runway into Q3 2024.
Progress toward BLA submission for EB-101 in RDEB in late Q2/early Q3 2023; pre-BLA meeting request submitted to FDA.
Additional Phase 3 VIITAL data presented at ISID; preclinical AAV ophthalmology data (ABO-504, ABO-503, ABO-505) at ASGCT May 16-20.
R&D expenses $8.0M, G&A $4.0M for Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

ABEONA THERAPEUTICS INC. reported the first quarter of 2023 results: revenue nil, net income Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share, EPS $0.54 loss per common share. Guidance reaffirmed.

Period: the first quarter of 2023
Revenue: nil
Net income: Net loss was $9.1 million for the first quarter of 2023, or $0.54 loss per common share
EPS: $0.54 loss per common share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the first quarter of 2023.

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-016277

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.